| Literature DB >> 12065789 |
L Douglas Case1, Gretchen Kimmick, Electra D Paskett, Kurt Lohman, Robert Tucker.
Abstract
The efficacy of a new cancer regimen is usually assessed by analyzing outcomes such as tumor response and overall survival. Many publications summarizing results of cancer clinical trials report measures such as odds ratios and hazard ratios, as these are the estimators of treatment effect obtained from regression models used to analyze the data. However, these measures are sometimes misinterpreted, as they are not necessarily familiar to many readers. The most common mistake is to interpret both measures as relative risks, an interpretation that can lead to an incorrect impression of the impact of the treatment on response and survival.Entities:
Mesh：
Year: 2002 PMID： 12065789 DOI： 10.1634/theoncologist.7-3-181
Source DB: PubMed Journal: Oncologist ISSN： 1083-7159